efficacy of oral levetiracetam in neonatal scizure

Evaluation of Success rate oral levetiracetam as add-on routin medication in neonat resistant seizures

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016051527896N1

Enrollment

Registered

2016-07-01

Start date

2016-04-13

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal seizures. Convulsions of newborn

Interventions

Levetiracetam tablets orally at a dose of 10 to 50 mg kg, 2 times a day, at least until the end of the neonatal period.

Treatment - Drugs

Levetiracetam tablets orally at a dose of 10 to 50 mg kg, 2 times a day, at least until the end of the neonatal period

Eligibility

Sex/Gender

All

Age

1 Days to 30 Days

Inclusion criteria

Inclusion criteria: inclusion criteria: neonates that admitted to the NICU; Neonatal ward in hospitals of Qom with seizure peresentation Exclusion criteria: hypoglycemia; hypocalcemia; Haypo magnesium; other electrolyte abnormalities

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Seizure frequency. Timepoint: During hospitalization. Method of measurement: Clinical presentation.	—

Secondary

Measure	Time frame
Side effects. Timepoint: During hospitalization. Method of measurement: Clinical and laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Reza Saadat

Hazrat Masumeh Hospital

a_saadati_md@yahoo.com+98 25 3665 1808

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026